Medtronic Stock Price, News & Analysis

Medtronic (NYSE: MDT) reported Q3 FY25 financial results with revenue of $8.3 billion, up 2.5% as reported and 4.1% organic. GAAP diluted EPS was $1.01, increasing 2%, while non-GAAP diluted EPS reached $1.39, up 7%.

Key performance highlights include strong growth in Cardiac Ablation Solutions (low-20s growth) driven by pulsed field ablation products, and Diabetes revenue increasing 8.4% as reported. The company maintained its full-year guidance, expecting organic revenue growth of 4.75% to 5% and FY25 diluted non-GAAP EPS between $5.44 and $5.50.

The Cardiovascular Portfolio revenue grew 3.7% as reported, Neuroscience Portfolio increased 4.4%, while Medical Surgical Portfolio decreased 1.9%. The company highlighted significant improvements in both gross margin and operating margin, marking the ninth consecutive quarter of mid-single digit organic revenue growth.

Medtronic (NYSE: MDT) has announced it will release its third quarter fiscal year 2025 financial results on Tuesday, February 18, 2025. The earnings release will be available at 5:45 a.m. CST, followed by a video webcast at 7:00 a.m. CST to discuss the results for the quarter that ended January 24, 2025.

The company has also outlined its upcoming earnings release schedule, including Q4 FY2025 results on May 21, 2025, and quarterly results for FY2026 scheduled for August 19, 2025, November 18, 2025, February 17, 2026, and May 20, 2026.

Medtronic, headquartered in Galway, Ireland, is a global healthcare technology company with 95,000+ employees across 150+ countries. Their technologies treat 70 health conditions, including cardiac devices, surgical robotics, insulin pumps, and patient monitoring systems.

Inogen (NASDAQ: INGN) announced changes to its Board of Directors, effective January 2025. Mira Kirti Sahney has been appointed as a new board member, while Tom West will retire after serving since April 2023.

Sahney brings significant medical device industry experience, currently serving on Claria Medical's board and previously as President of Medtronic's Pelvic Health Operating Unit (2021-2024). Her experience includes roles as CEO of Hyalex Orthopaedics, leadership positions at Smith + Nephew, and co-founding Myomo. She holds multiple engineering degrees from University of Michigan and Stanford, plus an MBA from MIT.

In her new role, Sahney will join Inogen's Compliance Committee and the Nominating and Governance Committee. The appointment aims to strengthen Inogen's position as a global leader in respiratory care.

Medtronic (NYSE: MDT) has appointed Thierry Piéton as Chief Financial Officer, effective March 3, 2025. Piéton, who joins from Renault Group where he served as CFO since March 2022, will report to Chairman and CEO Geoff Martha and join the Executive Committee.

Under Piéton's leadership at Renault, the company achieved record operating margins and improved free cash flow, while executing portfolio management through acquisitions, divestitures, and innovative partnerships. His experience spans healthcare and regulated manufacturing industries, including roles at Nissan Motor, General Electric, GE Healthcare, and PricewaterhouseCoopers.

Gary Corona, who has been serving as interim CFO, will transition to Senior Vice President, Corporate Finance and remain on the Executive Committee. During Corona's interim tenure, Medtronic delivered revenue growth and exceeded EPS expectations in the first and second quarters.

Medtronic (NYSE: MDT) announced that the Centers for Medicare & Medicaid Services (CMS) is initiating a national coverage analysis (NCA) for renal denervation procedures for hypertension patients. This analysis will help develop a national Medicare coverage policy for the Symplicity™ Spyral renal denervation system, a minimally invasive treatment for high blood pressure.

The NCA was initiated in response to Medtronic's request to support Medicare beneficiary access to the system. This follows Medtronic's collaboration with CMS on the Transitional Coverage for Emerging Technologies (TCET) pathway for the FDA-approved breakthrough device. The expected completion date for the national coverage analysis is October 11, 2025. Until then, Symplicity blood pressure procedures will continue to be evaluated for coverage based on individual Medicare patient medical necessity.

Medtronic (NYSE:MDT) has received CE Mark approval in the EU and UK for BrainSense™ Adaptive deep brain stimulation (aDBS) and BrainSense™ Electrode Identifier (EI). This marks a significant advancement in personalized DBS therapy for Parkinson's disease patients.

The BrainSense™ aDBS system is the world's only closed-loop DBS system that provides real-time, self-adjusting brain stimulation based on each patient's unique brain activity. The technology can dynamically adjust stimulation both in clinical settings and daily life. The BrainSense™ Electrode Identifier improves DBS programming by ensuring optimal initial contact selection in less time.

The first programming was completed by Dr. Martijn Beudel at Amsterdam University Medical Center. The technology will be available in Europe in early 2025, while FDA approval is pending in the United States. This innovation builds on Medtronic's 30-year history in DBS therapy, which has served over 185,000 people across 70 countries.

Medtronic plc (NYSE:MDT), the global healthcare technology leader based in Galway, Ireland, has announced its participation in the 43rd annual J.P. Morgan healthcare conference on Monday, January 13, 2025. Geoff Martha, chairman and CEO, will deliver a formal presentation and participate in a Q&A session starting at 2:15 p.m. PST.

The presentation and Q&A session will be accessible via live webcast through Medtronic's investor relations website, with an archived version available later that day. Medtronic employs over 95,000 passionate professionals across more than 150 countries, focusing on treating 70 health conditions through various technologies including cardiac devices, surgical robotics, insulin pumps, and patient monitoring systems. The company's mission centers on alleviating pain, restoring health, and extending life, helping two people every second globally.

Medtronic (NYSE: MDT) has declared a quarterly cash dividend of $0.70 per ordinary share for the third quarter of fiscal year 2025. The dividend will be payable on January 10, 2025, to shareholders of record as of December 27, 2024. This declaration aligns with the dividend increase announced in May 2024.

As a member of the S&P 500 Dividend Aristocrats index, Medtronic has maintained a 47-year streak of consecutive annual dividend increases. The company operates globally with 95,000+ employees across 150+ countries, focusing on healthcare technology solutions that address 70 different health conditions.

Medtronic addresses the environmental impact of healthcare technology, highlighting that the healthcare sector contributes to 4.6% of global greenhouse gas emissions. The company emphasizes three key approaches to sustainable healthcare: recognizing development timelines, reimagining products and packaging, and recruiting partners. Medtronic has installed 22 solar arrays across 16 locations, generating over 35 MWs of power, and signed a virtual power purchase agreement to cover nearly all U.S. energy needs. The company is focusing on sustainable product design through its Sustainability Development Center and emphasizes the importance of supply chain collaboration, as Scope 3 emissions account for over 90% of their carbon footprint.